Literature DB >> 8600660

Cryoglobulinemia in chronic hepatitis C virus infection: prevalence, clinical manifestations, response to interferon treatment and analysis of cryoprecipitates.

H Hartmann1, P Schott, F Polzien, S Mihm, A Uy, U Kaboth, I Pardowitz, G Ramadori.   

Abstract

Chronic hepatitis C virus infection can be associated with mixed cryoglobulinemia and systemic vasculitis. The pathogenesis remains poorly understood. 55 consecutive patients with chronic HCI infection (anti-HCV- and serum HCV RNA-positive) were studies prospectively. Cryoglobulinemia was detected in 28 patients (51%) with a mean cryocrit level of 2.2%. Clinical symptoms of vasculitis were encountered in six patients. Compared to those HCV-infected patients without cryoglobulinemia the following distinctive features were observed in the presence of cryoglobulinemia: increased age (p<0.02), female preponderance (p<0.002), longer-lasting HCV infection (mean of 10.7 vs. 4.7 yrs), higher prevalence of cirrhosis (42.8 vs. 0%), increased serum concentration of IgM and increased rheumatoid factor activity, decreased concentration of serum C4 (each p<0.05). The response to interferon treatment was similar in patients with and without cryoglobulinemia. When cryoprecipitates were analyzed by immunofixation, type II cryoglobulinemia was present in 1/3 and type III in 2/3 of patients. By SDS-PAGE four different proteins were demonstrable in cryoprecipitates each identified by immunoblotting as IgG and IgM heavy or light chains respectively. Cryoprecipitate IgGs were shown to react with HCV structural as well a non-structural proteins in a recombinant immunoblotting assay (RIBA). In contrast, cryoprecipitate IgMs reacted only to the HCV core protein c22-3. HCV RNA was detected in cryoprecipitates without a significant enrichment when compared to the corresponding serum or supernatant HCV RNA content. Given the monoclonality of some cryoprecipitate IgM and their reactivity to HCV core, a cross-reactivity to IgG was postulated. In fact, when performing a computer-assisted search for sequence homology, a motif within the core protein (EGLGWAGWL, conserved in HCV genotypes) was identified homologous to a sequence of IgG heavy chains. Thus, temperature-dependent affinity changes of IgM anti-HCV core (nonapeptide) and ensuing complex formation with IgG via binding to the homologous IgG sequence could be a mechanism of cryoprecipitate formation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8600660

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  6 in total

1.  Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis.

Authors:  P Lamprecht; F Moosig; A Gause; K Herlyn; E Csernok; H Hansen; W L Gross
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

2.  Prevalence of hepatitis-G virus and hepatitis-C virus infection in patients with non-Hodgkin's lymphoma.

Authors:  A Arican; T Sengezer; M Bozdayi; H Bozkaya; E Uçgül; D Dinçol; O Uzunalimoğlu
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

3.  Treatment of hepatitis C cryoglobulinemia: mission and challenges.

Authors:  Zeid Kayali; Douglas R Labrecque; Warren N Schmidt
Journal:  Curr Treat Options Gastroenterol       Date:  2006

4.  Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile.

Authors:  Martha Minopetrou; Emilia Hadziyannis; Melanie Deutsch; Maria Tampaki; Asimina Georgiadou; Eleni Dimopoulou; Dimitrios Vassilopoulos; John Koskinas
Journal:  Clin Vaccine Immunol       Date:  2013-03-06

Review 5.  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?

Authors:  Chalermrat Bunchorntavakul; Robert Mitrani; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2017-12-07

Review 6.  Autoimmune manifestations in viral hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  Semin Immunopathol       Date:  2012-07-28       Impact factor: 11.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.